← Connect Biopharma Holdings Limited (CNTB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Connect Biopharma Holdings Limited (CNTB)
Pharmaceutical Preparations · market cap $72M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-02
Conference
Pipeline
5
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Connect Biopharma Holdings (CNTB) is a small-cap clinical-stage biopharma with 62 employees and a ~$158M market cap, developing two Phase 2 assets: CBP-201 for moderate-to-severe persistent asthma and CBP-307 for moderate-to-severe ulcerative colitis. The company carries $46M in cash against a disclosed runway of ~8.6 months, with no current revenue following a drop from $26M in 2024 to zero in 2025, and an upcoming earnings catalyst on August 12, 2026.
The catalyst path
- 2026-10-02Conferenceimp 2/10
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CBP-201 | Phase 2 | Moderate to Severe Persistent Asthma |
| Double-Blind 0.2mg CBP-307 | Phase 2 | Moderate to Severe Ulcerative Colitis |
| umbilical cord blood (hUCB) cells | Phase 2 | Cerebral Palsy |
| Acetaminophen | Phase 3 | Patency of the Ductus Arteriosus |
| Rademikibart | Phase 2 | Asthma Acute |
Price & technical context
3-month
-60.2%
6-month
-64.0%
12-month
-35.1%
52-wk range
$0.98–$3.69
vs 50-day MA
-49.2%
vs 200-day MA
-58.4%
Realized vol
105.4%
Max drawdown
-73.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CNTB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.